Dr. Yongling Ji 季永领
Chief Physician
Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation and comprehensive treatment for thoracic tumors, including esophageal cancer, lung cancer, breast cancer, and thymoma. Special focus on comprehensive care for elderly patients with esophageal or lung cancer.
Dr. Ji is Director of the Thoracic Radiation Oncology Department and a Chief Physician at Zhejiang Cancer Hospital. Dr. Ji holds a doctoral degree and completed advanced studies at the Charité Medical Center, Humboldt University of Berlin, Germany.
Professional roles
- Member, Esophageal Cancer Group, Radiation Oncology Branch, Chinese Medical Association
- Member, Oncology Branch, Zhejiang Medical Doctor Association
- Member, Radiotherapy Professional Committee, Zhejiang Anti-Cancer Association
- Young Member, Tumor Radiotherapy Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Ji Yongling). Papers usually list the name as Yongling Ji or Ji Y.
Selected publications
50 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- JAMA Oncol, 2026 (first author): Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer: The R-ALPS Randomized Clinical Trial. PubMed 42955021
- JAMA Netw Open, 2026 (first author): Long-Term Outcomes of Concurrent Chemoradiotherapy With S-1 in Older Patients With Esophageal Cancer: A Secondary Analysis of a Randomized Clinical Trial. PubMed 41893843
- Cancer Pathog Ther, 2025 (senior author): Efficacy of local consolidative radiotherapy with first-line chemoimmunotherapy in synchronous oligometastatic esophageal squamous cell carcinoma. PubMed 41179941
- J Immunother Cancer, 2025 (senior author): Voxel-level radiomics and deep learning for predicting pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant immunotherapy and chemotherapy. PubMed 40090670
- J Thorac Dis, 2024 (senior author): Safety and feasibility of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophageal squamous cell carcinoma: a prospective single-group phase II clinical study. PubMed 39552849
- Eur Radiol, 2023 (senior author): Using clinical and radiomic feature-based machine learning models to predict pathological complete response in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiation. PubMed 37439939
- Psychooncology, 2022 (senior author): Psychological distress of cancer patients caused by treatment delay during the COVID-19 pandemic in China: A cross-sectional study. PubMed 35506550
- Oncotarget, 2017 (first author): A phase II study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. PubMed 29137320
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion